Завершено
Фаза I
Россия
CGC-11047 · Progen Pharmaceuticals
A Phase Ib Randomized Open Label Study Between Once-every-two-weeks and Once-every-four-weeks Treatment of CGC-11047 in Patients With CNV Due to Age Related Macular Degeneration